Loading
LEAP-002 randomised 794 patients with untreated advanced liver cancer to lenvatinib with or without pembrolizumab. Adding the immunotherapy did not lengthen life beyond lenvatinib alone, partly because the control arm did unusually well, a reminder that not every immunotherapy plus anti-angiogenic pairing works.
LEAP-002, trial NCT03713593 sponsored by Merck and Eisai and reported in 2022, found that adding pembrolizumab to lenvatinib did not extend life to a statistically significant degree in first-line unresectable hepatocellular carcinoma, a reminder that not every immunotherapy plus anti-angiogenic pairing works. It randomised 794 patients, and overall survival missed the prespecified boundary while progression-free survival was also not significant, with the lenvatinib control arm performing unusually well. OnCo links it to hepatocellular carcinoma, lenvatinib and pembrolizumab. Whether the failure reflects a strong comparator, the choice of PD-1 rather than PD-L1 blockade, or simple chance is the open question the trial left.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Hepatocellular carcinoma and the tag failure.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag failure.
Shares Small-molecule kinase inhibitors and the tag failure.
Shares Small-molecule kinase inhibitors and the tag failure.
Shares Small-molecule kinase inhibitors and the tag failure.
Shares Hepatocellular carcinoma and the tag failure.
Shares Small-molecule kinase inhibitors and the tag failure.
Shares Pembrolizumab and the tag failure.